JP2019536805A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536805A5 JP2019536805A5 JP2019530011A JP2019530011A JP2019536805A5 JP 2019536805 A5 JP2019536805 A5 JP 2019536805A5 JP 2019530011 A JP2019530011 A JP 2019530011A JP 2019530011 A JP2019530011 A JP 2019530011A JP 2019536805 A5 JP2019536805 A5 JP 2019536805A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- inhibitor
- administered
- cdk4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 68
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims 26
- 239000002246 antineoplastic agent Substances 0.000 claims 26
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 25
- 229960004562 carboplatin Drugs 0.000 claims 25
- 229960005420 etoposide Drugs 0.000 claims 24
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 24
- 229940127089 cytotoxic agent Drugs 0.000 claims 23
- 206010006187 Breast cancer Diseases 0.000 claims 12
- 208000026310 Breast neoplasm Diseases 0.000 claims 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 12
- 229960003852 atezolizumab Drugs 0.000 claims 12
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 12
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 11
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 11
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 11
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 11
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 11
- 238000011282 treatment Methods 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 238000012423 maintenance Methods 0.000 claims 9
- 206010041067 Small cell lung cancer Diseases 0.000 claims 7
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 7
- 229930012538 Paclitaxel Natural products 0.000 claims 6
- 229960004679 doxorubicin Drugs 0.000 claims 6
- 230000006698 induction Effects 0.000 claims 6
- 229960001592 paclitaxel Drugs 0.000 claims 6
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 6
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 4
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 4
- 239000012270 PD-1 inhibitor Substances 0.000 claims 4
- 239000012668 PD-1-inhibitor Substances 0.000 claims 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 4
- 229960004316 cisplatin Drugs 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 3
- 229940044683 chemotherapy drug Drugs 0.000 claims 3
- 229960004397 cyclophosphamide Drugs 0.000 claims 3
- 229960002949 fluorouracil Drugs 0.000 claims 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 3
- 229960005277 gemcitabine Drugs 0.000 claims 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 3
- 229960001756 oxaliplatin Drugs 0.000 claims 3
- 238000011287 therapeutic dose Methods 0.000 claims 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 2
- 229950002916 avelumab Drugs 0.000 claims 2
- 229950009791 durvalumab Drugs 0.000 claims 2
- 102000015694 estrogen receptors Human genes 0.000 claims 2
- 108010038795 estrogen receptors Proteins 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022091214A JP7483791B2 (ja) | 2016-12-05 | 2022-06-03 | 化学療法計画中の免疫応答の保護 |
| JP2023143202A JP7710496B2 (ja) | 2016-12-05 | 2023-09-04 | 化学療法計画中の免疫応答の保護 |
| JP2025115144A JP2025148426A (ja) | 2016-12-05 | 2025-07-08 | 化学療法計画中の免疫応答の保護 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662430302P | 2016-12-05 | 2016-12-05 | |
| US62/430,302 | 2016-12-05 | ||
| US201762479605P | 2017-03-31 | 2017-03-31 | |
| US62/479,605 | 2017-03-31 | ||
| PCT/US2017/064775 WO2018106729A1 (en) | 2016-12-05 | 2017-12-05 | Preservation of immune response during chemotherapy regimens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022091214A Division JP7483791B2 (ja) | 2016-12-05 | 2022-06-03 | 化学療法計画中の免疫応答の保護 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019536805A JP2019536805A (ja) | 2019-12-19 |
| JP2019536805A5 true JP2019536805A5 (enExample) | 2021-01-21 |
Family
ID=62491342
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019530011A Pending JP2019536805A (ja) | 2016-12-05 | 2017-12-05 | 化学療法計画中の免疫応答の保護 |
| JP2022091214A Active JP7483791B2 (ja) | 2016-12-05 | 2022-06-03 | 化学療法計画中の免疫応答の保護 |
| JP2023143202A Active JP7710496B2 (ja) | 2016-12-05 | 2023-09-04 | 化学療法計画中の免疫応答の保護 |
| JP2025115144A Pending JP2025148426A (ja) | 2016-12-05 | 2025-07-08 | 化学療法計画中の免疫応答の保護 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022091214A Active JP7483791B2 (ja) | 2016-12-05 | 2022-06-03 | 化学療法計画中の免疫応答の保護 |
| JP2023143202A Active JP7710496B2 (ja) | 2016-12-05 | 2023-09-04 | 化学療法計画中の免疫応答の保護 |
| JP2025115144A Pending JP2025148426A (ja) | 2016-12-05 | 2025-07-08 | 化学療法計画中の免疫応答の保護 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11529352B2 (enExample) |
| EP (1) | EP3548030A4 (enExample) |
| JP (4) | JP2019536805A (enExample) |
| KR (4) | KR20190092478A (enExample) |
| CN (3) | CN117530948A (enExample) |
| AU (4) | AU2017372856B9 (enExample) |
| BR (1) | BR112019011410A2 (enExample) |
| CA (1) | CA3045465A1 (enExample) |
| IL (4) | IL317919A (enExample) |
| MX (2) | MX2019006523A (enExample) |
| NZ (2) | NZ753631A (enExample) |
| WO (1) | WO2018106729A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105473140B (zh) * | 2013-03-15 | 2018-04-10 | G1治疗公司 | 在化学疗法期间对正常细胞的瞬时保护 |
| EP3138555B1 (en) | 2014-04-30 | 2020-10-28 | FUJIFILM Corporation | Liposome composition and production method therefor |
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| WO2018005863A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| CA3045465A1 (en) | 2016-12-05 | 2018-06-14 | G1 Therapeutics, Inc. | Preservation of immune response during chemotherapy regimens |
| EA201991622A1 (ru) | 2017-01-06 | 2020-01-23 | Г1 Терапьютикс, Инк. | Комплексная терапия для лечения рака |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| AU2018246024B2 (en) | 2017-03-31 | 2020-08-06 | Fujifilm Corporation | Liposome composition and pharmaceutical composition |
| WO2019054865A1 (en) * | 2017-09-14 | 2019-03-21 | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) | T-cell based immunotherapy |
| WO2019108589A1 (en) * | 2017-11-30 | 2019-06-06 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating cancer |
| PE20210121A1 (es) | 2018-01-08 | 2021-01-19 | G1 Therapeutics Inc | Regimenes de dosificacion superior de g1t38 |
| AU2019253706A1 (en) * | 2018-04-09 | 2020-11-26 | G1 Therapeutics, Inc. | Treatment of cancers having driving oncogenic mutations |
| PL3811931T3 (pl) * | 2018-06-20 | 2024-11-18 | Fujifilm Corporation | Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej |
| DK3811949T3 (da) * | 2018-06-20 | 2024-10-07 | Fujifilm Corp | Kombineret medicin omfattende gemcitabin-indkapslet liposomsammensætning og immun-checkpoint-blokade |
| WO2020058372A1 (en) * | 2018-09-19 | 2020-03-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy |
| WO2020071349A1 (ja) | 2018-10-01 | 2020-04-09 | 富士フイルム株式会社 | 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬 |
| JP2022506829A (ja) * | 2018-11-09 | 2022-01-17 | ジー１、セラピューティクス、インコーポレイテッド | エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン |
| WO2020219926A1 (en) * | 2019-04-24 | 2020-10-29 | The Trustees Of The University Of Pennsylvania | Treatment of cancer with cdk inhibitors |
| JP2022530674A (ja) * | 2019-05-03 | 2022-06-30 | ジェネンテック， インコーポレイテッド | 抗ｐｄ－ｌ１抗体を用いたがんの処置方法 |
| CN114222577A (zh) * | 2019-06-18 | 2022-03-22 | G1治疗公司 | 增强癌症患者中抗肿瘤免疫的患者选择 |
| EP4231089A3 (en) | 2019-11-12 | 2024-03-13 | Pointcloud Inc. | Dual path light detection and ranging system |
| WO2021110122A1 (zh) * | 2019-12-05 | 2021-06-10 | 基石药业（苏州）有限公司 | Cdk4/6抑制剂的组合疗法 |
| EP4652997A2 (en) | 2020-05-19 | 2025-11-26 | Pharmacosmos Holding A/s | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| CN116157403B (zh) * | 2020-06-15 | 2025-04-25 | 海南先声再明医药股份有限公司 | 曲拉西利的形态及其制造方法 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| TW202231283A (zh) * | 2020-10-19 | 2022-08-16 | 美商G1治療公司 | 用於治療轉移性大腸直腸癌之經改良之基於氟尿嘧啶之多藥劑化學治療 |
| EP4255576A4 (en) * | 2020-12-07 | 2024-10-23 | The Trustees of Indiana University | METHODS FOR SENSITIZING CANCER CELLS TO IMMUNE ATTACK USING ATRACTYLENOLIDE I |
| CN113788837B (zh) * | 2021-08-02 | 2022-08-26 | 深圳湾实验室坪山生物医药研发转化中心 | Trilaciclib的合成方法 |
| WO2023068220A1 (ja) * | 2021-10-18 | 2023-04-27 | 株式会社Preferred Networks | 予測方法及びバイオマーカー |
| WO2023164649A2 (en) * | 2022-02-25 | 2023-08-31 | Lanier Biotherapeutics, Inc. | Anti-alarmin binding molecules and treatment of pneumonitis |
| CN119816315A (zh) * | 2022-09-02 | 2025-04-11 | Rs肿瘤学有限责任公司 | 硫链丝菌素给药方案 |
| WO2024216208A2 (en) * | 2023-04-14 | 2024-10-17 | Concarlo Therapeutics, Inc. | Brk peptides and methods of use |
| WO2024238476A2 (en) * | 2023-05-15 | 2024-11-21 | Cedars-Sinai Medical Center | Y chromosome gene signature as a target for cancer therapy in combination with immunotherapy |
| CN117511855B (zh) * | 2023-11-09 | 2024-11-19 | 南京医科大学 | Epha抑制剂在诱导减数分裂中的应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0327380D0 (en) | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
| KR20080108517A (ko) | 2006-04-05 | 2008-12-15 | 노파르티스 아게 | 암을 치료하기 위한 치료제의 조합물 |
| EA200900799A1 (ru) | 2006-12-22 | 2009-12-30 | Новартис Аг | Гетероарилгетероарильные соединения как ингибиторы cdk, предназначенные для лечения рака, воспаления и борьбы с вирусными инфекциями |
| US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
| US8518930B2 (en) | 2008-07-29 | 2013-08-27 | Nerviano Medical Sciences S.R.L. | Therapeutic combination comprising a CDKS inhibitor and an antineoplastic agent |
| NZ591176A (en) | 2008-08-22 | 2012-11-30 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
| CA2738909A1 (en) | 2008-10-01 | 2010-05-06 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors |
| CN102231984A (zh) | 2008-10-01 | 2011-11-02 | 北卡罗来纳大学查珀尔希尔分校 | 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护 |
| US20120100100A1 (en) | 2009-05-13 | 2012-04-26 | Sharpless Norman E | Cyclin dependent kinase inhibitors and methods of use |
| US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| MX379532B (es) | 2010-10-25 | 2025-03-10 | G1 Therapeutics Inc | Inhibidores de cdk. |
| PH12013502697A1 (en) | 2011-07-01 | 2014-02-10 | Novartis Ag | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer |
| WO2013148748A1 (en) | 2012-03-29 | 2013-10-03 | Francis Xavier Tavares | Lactam kinase inhibitors |
| CA2870019C (en) | 2012-04-26 | 2020-08-18 | Francis Xavier Tavares | Synthesis of lactams |
| US20140271460A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Highly Active Anti-Neoplastic and Anti-Proliferative Agents |
| WO2014144596A2 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient protection of hematopoietic stem and progenitor cells against ionizing radiation |
| CN105473140B (zh) | 2013-03-15 | 2018-04-10 | G1治疗公司 | 在化学疗法期间对正常细胞的瞬时保护 |
| EP2983670A4 (en) | 2013-04-08 | 2017-03-08 | Pharmacyclics LLC | Ibrutinib combination therapy |
| MX2016000750A (es) * | 2013-08-02 | 2016-08-05 | Aduro Biotech Holdings Europe B V | Combinacion de agonistas de cd27 e inhibicion del punto de control inmunologico para estimulacion del sistema inmunologico. |
| US20160257688A1 (en) | 2013-10-24 | 2016-09-08 | Francis Xavier Tavares | Process for Synthesis of Lactams |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| WO2015161285A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation |
| KR20170003692A (ko) | 2014-05-15 | 2017-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료 |
| EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040848A1 (en) * | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| JP2017535528A (ja) | 2014-10-03 | 2017-11-30 | ノバルティス アーゲー | 組み合わせ治療 |
| EP3233123A4 (en) * | 2014-12-16 | 2018-05-09 | Bristol-Myers Squibb Company | Use of immune checkpoint inhibitors in central nervous systems neoplasms |
| WO2016126889A1 (en) * | 2015-02-03 | 2016-08-11 | G1 Therapeutics, Inc. | Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy |
| EP3471717A4 (en) | 2016-06-20 | 2020-01-22 | Kura Oncology, Inc. | Treatment of squamous cell carcinomas with inhibitors of erk |
| US11865176B2 (en) | 2016-11-08 | 2024-01-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of modulating anti-tumor immunity |
| EP3541389A1 (en) | 2016-11-16 | 2019-09-25 | Pfizer Inc | Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer |
| JP7166252B2 (ja) | 2016-11-30 | 2022-11-07 | メディツィーニシェ・ウニヴェルジテート・インスブルック | サイクリン依存性キナーゼ阻害剤としての３－アミノ－１，５－ジヒドロピラゾロ［３，４－ｄ］ピリミジン－４－オン |
| CA3045465A1 (en) | 2016-12-05 | 2018-06-14 | G1 Therapeutics, Inc. | Preservation of immune response during chemotherapy regimens |
| CN111148518A (zh) | 2017-03-30 | 2020-05-12 | 丹娜法伯癌症研究院 | 使用cdk4/6抑制剂调控调节性t细胞和免疫应答的方法 |
| WO2019108589A1 (en) | 2017-11-30 | 2019-06-06 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating cancer |
-
2017
- 2017-12-05 CA CA3045465A patent/CA3045465A1/en active Pending
- 2017-12-05 BR BR112019011410-6A patent/BR112019011410A2/pt not_active Application Discontinuation
- 2017-12-05 CN CN202311165935.0A patent/CN117530948A/zh active Pending
- 2017-12-05 NZ NZ753631A patent/NZ753631A/en unknown
- 2017-12-05 KR KR1020197019110A patent/KR20190092478A/ko not_active Ceased
- 2017-12-05 NZ NZ795224A patent/NZ795224A/en unknown
- 2017-12-05 IL IL317919A patent/IL317919A/en unknown
- 2017-12-05 IL IL303038A patent/IL303038B2/en unknown
- 2017-12-05 AU AU2017372856A patent/AU2017372856B9/en active Active
- 2017-12-05 KR KR1020247004108A patent/KR20240023676A/ko active Pending
- 2017-12-05 EP EP17878506.9A patent/EP3548030A4/en active Pending
- 2017-12-05 CN CN201780075215.1A patent/CN110035759A/zh active Pending
- 2017-12-05 MX MX2019006523A patent/MX2019006523A/es unknown
- 2017-12-05 WO PCT/US2017/064775 patent/WO2018106729A1/en not_active Ceased
- 2017-12-05 IL IL311265A patent/IL311265A/en unknown
- 2017-12-05 KR KR1020247004112A patent/KR20240024296A/ko active Pending
- 2017-12-05 JP JP2019530011A patent/JP2019536805A/ja active Pending
- 2017-12-05 CN CN202311165820.1A patent/CN117562905A/zh active Pending
- 2017-12-05 KR KR1020247004113A patent/KR20240023677A/ko not_active Withdrawn
-
2019
- 2019-05-26 IL IL266870A patent/IL266870A/en unknown
- 2019-06-04 MX MX2023006991A patent/MX2023006991A/es unknown
- 2019-06-05 US US16/432,244 patent/US11529352B2/en active Active
-
2022
- 2022-06-03 JP JP2022091214A patent/JP7483791B2/ja active Active
- 2022-12-01 US US18/072,963 patent/US20230302001A1/en active Pending
-
2023
- 2023-09-04 JP JP2023143202A patent/JP7710496B2/ja active Active
- 2023-12-11 AU AU2023282168A patent/AU2023282168B2/en active Active
- 2023-12-11 AU AU2023282170A patent/AU2023282170B2/en active Active
-
2025
- 2025-07-08 JP JP2025115144A patent/JP2025148426A/ja active Pending
- 2025-10-01 AU AU2025242155A patent/AU2025242155A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536805A5 (enExample) | ||
| US20230404999A1 (en) | Combination therapy with an antitumor alkaloid | |
| JP2019516711A5 (enExample) | ||
| JP2018508516A5 (enExample) | ||
| JP2024015120A5 (enExample) | ||
| JP2012506448A5 (enExample) | ||
| JP2017516802A5 (enExample) | ||
| JP2012180381A5 (enExample) | ||
| JP2011511072A5 (enExample) | ||
| Pincus et al. | Clinical trials documenting the efficacy of low-dose glucocorticoids in rheumatoid arthritis | |
| IL320452A (en) | Combination therapy for prostate cancer | |
| JP2020516646A5 (enExample) | ||
| RU2017102319A (ru) | Прерывистое введение ингибитора mdm2 | |
| JP2011529968A5 (enExample) | ||
| JP2018503610A5 (enExample) | ||
| RU2016151303A (ru) | Применение эрибулина в лечении рака | |
| JP2019508476A5 (enExample) | ||
| JP2016515586A5 (enExample) | ||
| JP2019517498A5 (enExample) | ||
| JP2014511383A5 (enExample) | ||
| Denlinger et al. | A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers | |
| Lee et al. | S-1 based doublet as an adjuvant chemotherapy for curatively resected stage III gastric cancer: results from the randomized phase III POST trial | |
| JP2004535441A5 (enExample) | ||
| CN102438608A (zh) | 包含ave8062和索拉非尼的抗肿瘤组合 | |
| JP2018519300A5 (enExample) |